Product category:
Contract research
News Release from: Galadeno
Edited by the Laboratorytalk Editorial
Team on 23 November 2004
Celgene and Galapagos in target
collaboration
Celgene will use adenoviral siRNA and cDNA libraries across its research programmes to study key disease pathways and identify novel drug targets
Celgene, a biopharmaceutical company with focus on the discovery, development and commercialisation of innovative therapies for unmet medical needs in cancer and inflammatory disease, and Galapagos, a target discovery and adenoviral services company, have entered into a multi-year target discovery collaboration Galadeno (Galapagos's wholly owned services unit) will provide Celgene with its adenoviral siRNA and cDNA libraries, SilenceSelect and FlexSelect
This article was originally published on Laboratorytalk on 24 Feb 2003 at 8.00am (UK)
Related stories
First spinal study of bone substitute
Study will measure performance of synthetic bone graft substitute in 30 patients undergoing spinal fusion for degenerative disc disease
Acquisition creates global CRO
Advanced Clinical Sciences becomes a global player in clinical research with the takeover of a Swiss CRO called CRC
These libraries enable the knock-down or over-expression of the human drugable genome in human primary cell assays.
Celgene will use these libraries across Celgene's research programmes to study key disease pathways and identify novel drug targets.
"Galadeno is unique in the siRNA field right now, due to its in depth experience of not only providing tools, but also applying them in complex biological assays", said Celgene's CSO, David Stirling.
"This expertise, combined with their robust technology platform gives us confidence regarding the discovery prospects for this collaboration.
"We are delighted to be working with Celgene which is one of the most exciting biopharmaceutical companies in their field," said Onno van de Stolpe, CEO of Galapagos.
"We are also very pleased that Celgene has joined the growing number of companies that have chosen to use our adenoviral siRNA and gene expression technologies to drive their target and drug discovery effort.".
• Galadeno: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
